Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595559 | 0.84 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL9975343 | 0.84 | PDGFRB (0.62) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL14809875 | 0.84 | CYP1A2 (0.49) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL7712834 | 0.83 | PDGFRB (0.58) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL19354405 | 0.82 | PDGFRB (0.76) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL10714392 | 0.82 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL19181062 | 0.80 | SIGMAR1 (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL17466154 | 0.80 | CA12 (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31722848 | 0.79 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31726681 | 0.79 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773642-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | Afraxis Holdings, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013067423-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067423-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-0865421-B1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LTD (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-6048872-A | DIETETICS; ANTIDIABETIC AGENTS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO WELLCOME INC. (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0865421-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021665-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | PAK2, PAK3, PAK1 | PDGFRB 233/4885FGFR1 478/4885PDGFRA 229/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | PDGFRB 460/4885FGFR1 766/4885PDGFRA 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.